Edition:
India

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

3.65USD
2:29am IST
Change (% chg)

$-0.02 (-0.54%)
Prev Close
$3.67
Open
$3.69
Day's High
$3.72
Day's Low
$3.59
Volume
14,573
Avg. Vol
66,149
52-wk High
$5.59
52-wk Low
$1.93

Chart for

About

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $180.60
Shares Outstanding(Mil.): 34.14
Dividend: --
Yield (%): --

Financials

BRIEF-Perceptive Advisors Reports 9.9 Pct Passive Stake In Agile Therapeutics

* Perceptive Advisors LLC Reports A 9.9 Pct Passive Stake In Agile Therapeutics Inc As Of Dec 22, 2017 - SEC Filing Source text: (http://bit.ly/2FlgqN8) Further company coverage:

09 Jan 2018

FDA rejects Agile's contraceptive patch, shares plunge

Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its contraceptive patch for the second time, sending the drug developer's shares down about 50 percent.

22 Dec 2017

FDA declines to approve Agile's contraceptive patch

Dec 22 Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve the company's contraceptive patch, citing deficiencies related to its adhesion test methods.

22 Dec 2017

BRIEF-Agile Therapeutics Gets Response Letter From FDA For Pregnancy Prevention Drug Twirla

* AGILE THERAPEUTICS, INC. RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY

22 Dec 2017

BRIEF-Agile Therapeutics Q3 loss per share $0.22

* Agile therapeutics reports third quarter 2017 financial results

07 Nov 2017

Earnings vs. Estimates